Multiple Sclerosis: Extended Dosing of Natalizumab Reduces Risk of PML

MedicalResearch.com Interview with:

Lana Zhovtis Ryserson, MDAssistant Professor, Department of NeurologyNYU Langone Health

Dr. Zhovtis Ryserson

Lana Zhovtis Ryserson, MD
Assistant Professor, Department of Neurology
NYU Langone Health

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Natalizumab is an effective therapy of relapsing remitting multiple sclerosis dosed at 300mg every 4 weeks. However it is associated with a potentially deadly infection – progressive multifocal leukoencephalopathy. In order to mitigate this risk, clinicians have adopted an approach of infusing the medication less frequently, a strategy which has become known as Extended Interval Dosing (EID).

The TOUCH database is US mandatated risk evaluation and mitigation program which is the largest database available to assess PML risk for patients on EID schedule. Previous analysis of this database in 2017, showed a significant risk reduction of PML in patients utilizing extended interval dosing schedule. The aim of the current study was to update on this analysis with another year of data.

MedicalResearch.com: What should readers take away from your report? 

Response: The results of this study reinforce the finding that patients treated on extended interval dosing schedule have significantly lower risk of PML than patients who remain on standard interval dosing.  

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response:  This study can not offer information efficacy of Natalizumab dosed at extended interval dosing schedule since efficacy data is not captured in the TOUCH database. There is now an ongoing randomized control trial which will help inform on whether the efficacy of Natalizumab is maintained on EID schedule.

This study was supported by Biogen

Citation:

AAN 2019 abstract:

Reduced risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab extended interval dosing (EID): updated analysis of the TOUCH® Prescribing Program database

May 7, 2019 @ 4:21 pm 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.